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ABSTRACT
Allergic asthma is the most frequent disease of the respiratory tract. The aim of the current experimental and clinical studies was 
to find new sources of drugs able to control asthmatic inflammation and airway hyperresponsiveness. Our experimental studies 
were focused on efficiency evaluation of substances able to influence activities of ion channels, phosphodiesterase (PDE) isoforms, 
substances from the group of polyphenols and NO metabolism modulators during experimentally induced allergic asthma. 
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smooth muscle hyperreactivity and the degree of inflam-
mation of the airways. Different experimental models 
of airways hyperreactivity were used for experimental 
simulation and of allergic asthma. We utilized the model 
of guinea pig airways hyperreactivity induced by aller-
gen – ovalbumin (OVA) parenteral administration and 
inhalation.
Allergic asthma and nitric oxide metabolism
The precise pathomechanism of airway hyperreactivity is 
unknown but many studies assume that nitric oxide (NO) 
plays a very important role in this process (Ricciardolo, 
2003). We studied the effects of the modulation of NO 
level on the airways smooth muscle response in condi-
tions of experimental hyperreactivity at three levels: the 
level of the precursor changes (L-arginine supplementa-
tion or treatment with drugs releasing this molecule – NO 
donors); activity of enzymes involved in NO homeostasis 
(NO synthases – NOS, arginases); and mechanism of NO 
action (guanylylcyclase). The changes in NO metabo-
lism during allergic inflammation were compared with 
pathological NO changes induced by a chemical trigger 
– exogenous irritant, i.e. toluene vapor. 
For the changes of NO production, we used inhibition 
o f  N O S  a ctivi ty  b y  n o n - s pecifi c  ( N ω-nitro-L-arginine 
methyl ester – L-NAME) or specific inhibitor (amino-
guanidine – AG). They were applied in vivo during two 
therapeutic regimens (acute or chronic) in toluene- or 
allergen-induced hyperreactivity in guinea pigs. It is 
Introduction
Allergic asthma is a chronic inflammatory disease of 
the airways. Characteristic features of allergic asthma 
are allergen-induced early and late bronchial obstructive 
reactions, airway inflammation, structural changes of the 
airway wall associated with progressive decline in lung 
function, and airway hyperresponsiveness (AHR). AHR 
is defined by an exaggerated obstructive response of the 
airways to a variety of pharmacological, chemical and 
physical stimuli (Meurs et al., 2008)
In addition to smooth muscle hyperreactivity, allergic 
asthma is associated with ongoing airway inflammation, 
infiltration of the airway wall by inflammatory cells (eosin-
ophils, lymphocytes, especially CD4-positive T-cells) and 
formation of Th2 cytokines (IL-4, IL-5, IL-13), which play 
a key role in orchestrating the eosinophilic inflamma-
tory response (Antoniu, 2009). Inflammation is thought 
to cause symptoms of asthma directly and indirectly by 
inducing contraction of airway smooth muscle, enhancing 
airway responsiveness to various stimuli and by inducing 
changes in structural components of the airway wall 
leading to airway remodelling (Zuyderduyn et al., 2008). 
The aim of our experimental studies related to allergic 
asthma was to find new sources of drugs able to modulate 
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interesting that we recorded a significant decrease of 
tracheal smooth muscle reactivity after acute L-NAME 
pre-treatment in toluene-induced hyperreactivity but 
an opposite effect, increase of tracheal smooth muscle 
reactivity, in allergen-induced hyperreactivity after acute 
and chronic L-NAME pre-treatment. The lung tissue 
reactivity was reduced after acute and chronic L-NAME 
pre-treatment in toluene-induced hyperreactivity but 
changes in allergen-induced hyperreactivity were non-
significant. Our study demonstrated that the effect of 
NOS inhibitors on the airway reactivity changes was 
dependent on the hyperreactivity provoking factor and 
type of therapeutic regimen. Constitutive isoforms of 
NOS have probably a more significant role in allergen-
induced airways hyperreactivity than in toluene-induced 
hyperreactivity (Antošová et al., 2008).
The limitation of L-arginine bioavailability by arginase 
for NO synthesis may contribute to airway hyperreactiv-
ity. We investigated the effect of changes in arginase activ-
ity in ovalbumin-induced airway hyperreactivity after in 
vitro administration of arginase or non-selective inhibitor 
of arginase Nω-hydroxy-L-arginine (NOHA) (Antošová et 
al., 2006). We did not record significant differences in the 
reactivity of tracheal and lung tissue smooth muscle if we 
applied arginase in vitro. NOHA in vitro induced a dose-
dependent decrease of tracheal and lung tissue smooth 
muscle reactivity (Strapková and Antošová, 2009). The 
supplemention of L-arginine together with NOHA in 
vitro intensified the decrease of the airways reactivity 
ind uced by an inhibition of arginase, confirming the  
importance of the optimal level of L-arginine for control 
of bronchomotor tone. 
Since NOS and arginase compete for the common 
substrate L-arginine, we analysed the response of tracheal 
and lung tissue smooth muscle after administration of 
inhibitors of NOS – (L-NAME and AG) and the inhibi-
tor of arginase (NOHA) in combinations under in vitro 
conditions. We found a decrease of ovalbumin-induced 
hyperreactivity if we used the combination of NOS and 
arginase inhibitors. Simultaneous inhibition of iNOS 
( A G ) an d arginase (NO HA ) ev ok ed th e m ost exp r es-
sive effect. Inhibition of both enzymes caused a more 
expressive effect in tracheal smooth muscles than in the 
lung. The results point out the importance of an optimal 
balance in the activity of NO synthases and arginase. 
They confirmed that competition of NO synthases and 
arginase for the common substrate L-arginine may be 
one of the important factors influencing the condition 
of the bronchomotoric tone in the airway hyperreactivity 
(Strapková et al., 2008, Strapková and Antošová, 2011). 
Allergic asthma and modulated 
activity of ion channels
Allergic inflammatory disease of the airways is a sophis-
ticated process, mostly characterized by representative 
histopathological features associated with typical clinical 
symptoms. Development of allergic airways inflammation 
is closely associated with modulated activity of calcium 
and potassium ion channels resulting in production 
of antigen-specific antibodies, qualitatively changed 
mucus output, mast cell differentiation and airways 
eosinophilia (Pelaia et al., 2002). Thus, ion channels 
activity is finally responsible for clinical manifestations 
as obstruction, hyperreactivity and airways remodeling, 
as well as pathological cough. Modern pharmacotherapy 
of bronchial asthma is based on regularly administered 
disease controllers (e.g. inhaled corticosteroids, long-
acting β2-adrenomimetics (LABA), selective inhibitors of 
PDE, etc.) and actually applied relievers (e.g. short-acting 
β2-adrenomimetics (SABA) or anticholinergics) (Beckett 
et al., 2003). All these drugs from miscellaneous phar-
macological groups have one common attribute: their 
mechanism of action is partly mediated via changed 
activity of certain ion channels (calcium, potassium or 
chloride) type. Recent knowledge concerning asthma 
pathophysiology and the role of ion channels has opened 
the possibility of finding tissue-selective ion channel 
modulators as a novel target for asthma therapy. 
Potassium ion channels
Previously, it was shown that activation of K+
ATP as well 
as BK+
Ca ion channels in airways of unsensitised guinea 
pigs resulted in significant suppression of cough reflex 
and bronchoconstriction experimentally induced by citric 
acid aerosol (Sutovska et al., 2007). Recently we tested the 
influence of developing allergic inflammatory reaction on 
the relationship between defense reflexes of the airways 
and the activity of both potassium ion channel types in 
guinea pigs sensitised by ovalbumin. The influence on 
cough reflex was assessed using the method of citric acid 
induced cough. The airways smooth muscle reactivity in 
vivo was evaluated by actual values of specific airways 
resistance (RV) according to Pennock et al. (1979). It was 
found that the defense role of K+
ATP remained almost 
unchanged even in conditions of allergic inflammation, 
while the role of BK+
Ca decreased progressively according 
to the degree of allergic inflammation (Sutovska et al., 
2009) (Figure 1). A further important fact was observed 
after single applied doses: agonists of both potassium 
ion channels significantly increased an infiltration of 
pulmonary tissue by lymphocytes and augmented pulmo-
nary eosinophilia. All these findings corresponded with 
further literature data (Duffy et al., 2001) and pointing 
out the involvement of potassium ion channels in the 
development of allergic inflammation. 
Calcium ion channels
Highly Ca2+-selective, store-operated (CRAC) ion chan-
nels (calcium-activated calcium ion channels) represent 
one of the TRP superfamily channels (transient receptor 
potential), so-called store-operated channels (SOCs), 
regulating intracellular transport and metabolism of 29
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calcium ions and playing a key role in most cellular pro-
cesses (Frischauf et al., 2008). Detailed examination of 
the function of CRAC channels located in mast cells and 
lymphocytes showed association with massive produc-
tion of proinflammatory mediators. Previously, Peel et al. 
(2008) showed expression and role of CRAC ion channels 
in contracting activity of human airways smooth muscle. 
Our experimental studies revealed that the CRAC ion 
channel antagonist 3-fluoropyridine-4-carboxylic acid 
(FCA) was an antitussive and bronchodilatory active 
agent. Intraperitoneally administered FCA in doses of 
1.3, 1.5 and 1.7 mg.kg–1 caused statistically significant 
and dose-dependent decrease of NE (number of cough 
efforts) in conscious OVA-sensitized guinea pigs, which is 
comparable to the suppressive effect of the centrally act-
ing antitussive agent codeine tested in the control group 
(dose 10 mg.kg–1 i.p., Figure 2). The values of specific 
airways resistance (RV) were significantly suppressed, 
similarly as antitussive activity, in a dose-dependent 
manner, regardless of the bronchoconstrictor used (citric 
acid c=0.3 M or histamine c=10–6 M/l). Besides, the high-
est experimental dose of the CRAC antagonist exerted a 
bronchodilatory effect which exceeded the activity of the 
control drug-salbutamol. 
It can be summarized that the presented experiments 
confirmed the specific role of plasmalemmal potassium 
and intracellular calcium ion channels in the patho-
physiology of disorders accompanied by allergic airways 
inflammation. K+
ATP ion channels retained their defense 
property despite the developing allergic airways inflam-
mation, while the role of BK+
Ca progressively changed. 
Accordingly, K+
ATP represents a more rational therapeutic 
target for novel antiasthmatic drugs. However, introduc-
tion of K+
ATP agonists in clinical practice is strongly limited 
by their proinflammatory effects. Agents antagonizing the 
function of CRAC calcium channels appear to be promis-
ing. They may represent a new antiasthmatic therapeutic 
trend due to their antitussive and bronchodilatory effects 
and the influence of immune cell-key pathomechanisms 
of allergic airways inflammation. 
Hyperreactivity of airways and 
phosphodiesterase (PDE) inhibitors
At our department we have been focused for several years 
on a pharmacological modulation of the smooth muscle 
activity in the airways and of the cough reflex by various 
agents affecting the activity of PDE, i.e. xanthine deriva-
tives and PDE inhibitors. 
In the therapy of airway diseases associated with cough 
and inflammation, such as bronchial asthma and chronic 
obstructive pulmonary disease (COPD), several xanthine 
derivatives are still used. They are generally considered 
to be non-selective inhibitors of PDE. Nevertheless, in 
therapeutically relevant plasma concentrations several 
other mechanisms are involved in their effects, e.g. 
antagonism of adenosine receptors, activation of histone-
deacetylases and others (for review see Mokra and Mokry, 
2007). Furthermore, low specificity of their mechanism 
of action, interactions with other drugs, and a narrow 
therapeutic range can often lead to occurrence of adverse 
effects, which can limit their use as antitussives (Antoniu, 
2006). Therefore on using selective or dual PDE inhibitors 
in the therapy of these diseases and in affecting cough 
their effect should be better understood. 
Bronchodilation and an anti-inflammatory action 
of non-selective PDE inhibitors has been only partially 
elucidated and  little is known about the antitussive 
effects of xanthine derivatives (Mokry et al., 2008) or 
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Figure 1. Changes of specifi  c airway resistance (left side – R.V) and number of cough eff  orts (right side – NE) on administration of K+
ATP 
agonist (pinacidil) and BK+
Ca agonist (NS 1619 OVA 21 AC) measured in guinea pigs sensitized by ovalbumin (on 21st day of sensitization) 
and compared with control drugs (R.V – salbutamol and NE – codeine). *p<0.05; **p<0.01. 30
Soňa Fraňová, Alena Strapková, Juraj Mokrý, et al. 
Pharmacologic modulation of experimentally induced allergic asthma
ISSN: 1337-6853 (print version) | 1337-9569 (electronic version)
selective PDE inhibitors (PDE3, PDE4, PDE5) (Fujimura 
and Liu, 2007). Selective inhibitors of PDE have attracted 
increasing attention in the therapy of respiratory diseases 
(Chung, 2006). PDE isoenzymes play an important role 
in the regulation of airways diameter and smooth muscle 
functions. PDE3 and PDE4, both hydrolyzing cAMP, 
were confirmed as major PDE isoforms in the airways. 
H o w e v e r ,  ai rw a y  s m o o t h  m u s c l e  c o n t ai n s  m o r e  P D E  
isoenzymes, e.g. PDE1,3,4,5 and 7. 
The antitussive properties of xanthine derivatives 
theophylline and theobromine as non-selective PDE 
inhibitors on citric acid induced cough were studied. 
Furthermore, the participation of PDE1, PDE3, PDE4, and 
PDE5 isoenzymes in cough and antitussive effects of their 
selective inhibitors was assessed at our department. 
The administration of some xanthine derivatives (ami-
nophylline, caffeine, and theophylline) led to a significant 
decrease of specific airway resistance, associated with 
changes in minute ventilation caused predominantly by 
influencing the frequency of breathing. The previously 
demonstrated antitussive effect of intraperitoneally 
administered theophylline to conscious cats after 
mechanical stimulation of the laryng  was confirmed 
also in a model of chemically induced cough in guinea 
pigs. The antitussive activity of theophylline was even 
higher compared to the commercially used non-narcotic 
antitussive dextromethorphan as well as other agents of 
plant origin, e.g. Emblica officinalis, Paederia foetida, etc. 
(Nosalova et al., 2003; Nosalova et al., 2007). Furthermore, 
we demonstrated a significant decrease in the number of 
cough efforts evoked by citric acid inhalation in healthy 
guinea pigs after administration of xanthine derivatives 
theophylline and theobromine (Mokry et al., 2009). 
Similar results were found after 14 days of ovalbumin 
sensitization, with significant increases of specific airway 
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resistance after inhalation of saline, citric acid, and his-
tamine. Theophylline and theobromine, however, sig-
nificantly suppressed the specific airway resistance only 
in sensitized animals. The in vitro evaluation confirmed 
the beneficial effect of intraperitoneally administered 
theophylline and theobromine following ovalbumin 
sensitization. Both xanthine derivatives decreased the 
in vitro airway reactivity compared to the guinea pigs 
without treatment (Mokry et al., 2009). 
A significant part of our research was dedicated to the 
evaluation of antitussive and bronchodilating activities of 
selective PDE inhibitors (Mokry and Nosalova, 2011). In 
our experiments with healthy non-sensitized guinea pigs, 
we demonstrated the antitussive action of vinpocetin, the 
selective PDE1 inhibitor, cilostazol, the selective PDE3 
inhibitor, and of zaprinast, the selective PDE5 inhibi-
tor. Their effect was accompanied by decreased in vivo 
airway reactivity to histamine. In ovalbumin-sensitized 
animals, a significant antitussive activity was found after 
administration of vinpocetin, zaprinast and citalopram, 
the selective PDE4 inhibitor, with simultaneous decrease 
of in vivo airway reactivity to ovalbumin. The in vivo 
response to inhalation of histamine in sensitized animals 
was influenced only after administration of cilostazol and 
zaprinast, suggesting participation of PDE3 and PDE5 in 
inflammatory processes and airway hyperresponsiveness 
evoked by repeated sensitization by ovalbumin. In vitro 
experiments confirmed beneficial effects of intraperi-
toneally administered cilostazol and citalopram in both 
healthy and ovalbumin-sensitized animals. Currently, 
activity of PDE7 inhibitor BRL 50491 and its combination 
with rolipram (PDE4 inhibitor) and salbutamol (beta2-
agonist) is being evaluated. Preliminary results showed 
significant suppression of inflammation and cough in 
ovalbumin-sensitized animals.
Concluding these results, we can confirm that in future 
the selective inhibition of PDE (especially subtypes 3, 4, 
and 7) as well as xanthine derivatives with their manifold 
pharmacological properties may assume their position in 
the therapy of cough and some diseases associated with 
bronchial hyperresponsiveness. Their anti-inflammatory 
potential in the therapy of inflammation and airway 
hyperresponsiveness will be utilized, together with their 
relaxing effect on smooth muscle. 
Prevention of asthma and 
polyphenolic substances
Recently increasing attention has been paid to the use of 
polyphenolic substances in the field of respiratory tract. 
Polyphenols represent important bioactive molecules in 
plant foods and possess many biological activities in the 
airways. They are able to inhibit the release and synthesis 
of bronchoconstricting mediators and to impair the 
increased amount of inflammatory cytokines, chemo-
kines, eosinophils and allergen species antibodies during 
immunoallergic airway inflammation resulting in bron-
chodilatory and antiinflammatory effects. Furthermore, 
epidemiological studies contain data supporting the idea 
that health benefits associated with fruits, vegetables and 
red wine in the diet are probably linked with polyphenols 
that most likely reduce the occurrence of asthma symp-
toms (Varraso et al., 2009).
In light of these finfiongs, polyphenols became the 
object of our interest in experimental research of allergic 
asthma. Of the large group of these natural substances, 
p r o d u cts  wi th  hi gh  c o n c e n tr a ti o ns  o f  fl a v o n o i ds  an d  
resveratrol as a polyphenolic compound (Provinol and 
Flavin7®), a flavonol (quercetin) and stilbene (resveratrol) 
have been used.
Our studies were aimed at the influence of polyphe-
nols on airway hyperreactivity and allergic inflammation 
in experimental conditions of allergic asthma after their 
short- or long-term administration. Experiments were 
realized under in vitro and in vivo conditions in order to 
evaluated airway reactivity provoked by bronchoconstric-
tor mediators. To confirm a probable antiinflammatory 
effect of polyphenols, these experiments were supple-
mented with bronchoalveolar lavage and histological 
examination of the trachea and lung tissues. 
In our experiments, the following results were obtained 
during monitoring the short-term effect of polyphenols. 
During in vivo conditions, a single oral dose of Provinol, 
Flavin7®, quercetin and resveratrol caused a significant 
decrease of specific airway conductance. During in vitro 
experiments, polyphenols decreased the amplitude of 
contraction in response to bronchoconstrictor mediators 
(Franova et al., 2007, Joskova et al., 2009). 
After long-term administration, only a mixture of the 
polyphenolic compounds Provinol and Flavin7 confirmed 
the ability to reduce airway hyperreactivity during both in 
vivo (Figure 3) and in vitro conditions. 
The antiinflammatory properties of polyphenols were 
evaluated after long-term administration using quanti-
fication of proinflammatory cytokines IL-4 and IL-5 in 
bronchoalveolar lavage and eosinophils in the tracheal 
mucosa and lung tissue. Our results showed antiinflam-
matory properties of combined polyphenolic compounds 
in the airways (decrease IL-4, IL-5 levels and eosinophil 
account), but not of polyphenols alone (Franova et al., 
2009; 2011; Joskova et al., 2011). 
In conclusion, we can summarize the most important 
findings of our experiments. The polyphenolic com-
pounds Provinol and Flavin7® posseses efficient antiasth-
matic activity. They cause bronchodilation and also sup-
press asthmatic inflammation in the airways. Quercetin 
and resveratrol are able to induce acute bronchodilation 
without antiinflammatory effects. We thus assume that 
individual components in polyphenolic compounds 
can positively influence each other. Our findings are in 
agreement with some epidemiological studies in which 
polyphenols caused amelioration of asthma symptoms.
Nowadays, experimental research of allergic asthma 
continues in our Department of Pharmacology. It is aimed 
at comparing the effects of polyphenols in the airways 
and classic treatment of asthma recommended by asthma 
guidelines. 32
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